Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 2;129(6):669–683. doi: 10.1161/CIRCRESAHA.120.318577

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors.

Circulation Research is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 4. — Expression of the lncRNA GAS5 decreases in the absence of SRSF4 (serine/arginine splicing factor 4).A, Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of GAS5 expression in the hearts of control and SRSF4 KO mice from birth to adulthood. Data are shown as mean±SEM; n=4 mice per group, except for P1 groups (n=5). **P<0.01, ***P<0.001 SRSF4 KO vs control; 2-way ANOVA followed by Bonferroni posttest. B, Expression profile of GAS5 in the hearts of wild-type mice from embryonic development to adulthood. Data are shown as mean±SEM; n=3 mice per group, except for the E17.5 group (n=4). *P<0.05; Kruskal-Wallis test followed by Dunn Multiple comparison test. C, qRT-PCR analysis of GAS5 expression in control and SRSF4 KO neonatal cardiomyocytes treated with ActD. Values for each treatment time point were normalized to the mean basal (untreated) value and to the mean value for control cells treated with DMSO (dotted line). Data are shown as mean±SEM, n=3 per group. **P<0.01 SRSF4 KO vs control; 2-way ANOVA followed by the Bonferroni posttest. D and E, qRT-PCR analysis of GAS5 (D) and GADD45 (E) expression in control and SRSF4 KO neonatal cardiomyocytes treated with vehicle (DMSO, control) or with nonsense-mediated decay (NMD) inhibitor for7 h. Values were normalized to the mean value of each group treated with DMSO. Data are shown as mean±SEM, and symbols represent individual samples from one experiment. n=5. *P<0.05, **P<0.01, ***P<0.001 for control vs NMD inhibitor. Two-way ANOVA followed by Bonferroni correction.